ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - infliximab - תמיסה להזרקה - infliximab 120 mg/ml - infliximab

ישראל - עברית - Ministry of Health

novartis israel ltd - secukinumab - תמיסה להזרקה - secukinumab 150 mg/ml - secukinumab

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - tocilizumab - תמיסה להזרקה - tocilizumab 162 mg / 0.9 ml - tocilizumab

ישראל - עברית - Ministry of Health

samsung bioepis il ltd, israel - etanercept - תמיסה להזרקה - etanercept 50 mg/ml - etanercept

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - adalimumab - תמיסה להזרקה - adalimumab 50 mg / 1 ml - adalimumab

ישראל - עברית - Ministry of Health

samsung bioepis il ltd, israel - adalimumab - תמיסה להזרקה - adalimumab 50 mg/ml - adalimumab

ישראל - עברית - Ministry of Health

dexcel ltd, israel - adalimumab - תמיסה להזרקה - adalimumab 50 mg/ml - adalimumab

ישראל - עברית - Ministry of Health

j-c health care ltd - golimumab - תמיסה להזרקה - golimumab 50 mg / 0.5 ml - golimumab - golimumab - rheumatoid arthritis :simponi, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis when the response to disease-modifying anti-rheumatic drug (dmard) therapy including mtx has been inadequate.psoriatic arthritis :simponi, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active and progressive psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate.ankylosing spondylitis :simponi is indicated for the treatment of adult patients with severe active ankylosing spondylitis who have responded inadequately to conventional therapy.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg/ml - rituximab - rituximab - mabthera is indicated for the following indications: * non-hodgkin’s lymphoma (nhl)mabthera is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, b-cell non-hodgkin’s lymphoma.mabthera is indicated for the treatment of previously untreated patients with low-grade or follicular lymphoma in combination with chemotherapy mabthera is indicated for the treatment of patients with cd20 positive diffuse large b-cell non-hodgkin's lymphoma in combination with chop chemotherapy. mabthera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. * chronic lymphocytic leukaemia (cll)mabthera in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including mabthera or patients refractory to previous mabthera plu

ישראל - עברית - Ministry of Health

j-c health care ltd - ustekinumab - תמיסה להזרקה - ustekinumab 45 mg / 0.5 ml - ustekinumab - ustekinumab - stelara™ is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to,or have contraindication to or who are intolerant to other systemic therapies including ciclosporin,methotrexate and psoralen plus u.v (puva).